Skip to main content
. 2019 Sep 24;25:7182–7190. doi: 10.12659/MSM.916428

Figure 2.

Figure 2

Antifibrotic effects of bone marrow-derived mesenchymal stem cells (BM-MSCs) in the mouse model of liver fibrosis. Thirty C57BL/6 mice were randomly divided into the control group (n=10), the model group (n=10), and the BM-MSC-treated model group (n=10). (A) Liver injury was assessed by measurement of serum levels of alanine aminotransferase (ALT). (B) Liver injury was assessed by serum levels of aspartate aminotransferase (AST). (C) The gross morphology of the mouse liver (a–c) (magnification ×100). Photomicrographs of the mouse liver stained with hematoxylin and eosin (H&E) (d–f) (magnification ×100). Photomicrographs of the mouse liver stained with Masson’s trichrome (g–i) (magnification ×100). (D) Expression of collagen I in each group. (E) Expression of alpha-smooth muscle actin (α-SMA) in each group. # Compared with the control group (p<0.05); * compared with the model group (p<0.05).